ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Immunogenetics of Visceral Leishmaniasis

This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), July 2008

Sponsored by: National Human Genome Research Institute (NHGRI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00342823
  Purpose

This study will examine what causes some people to develop the fatal disease visceral leishmaniasis (VL) in South America. The disease is brought about by the protozoan Leishmania chagasi. Several studies have documented clustering of the disease within families. There seems to be a genetic contribution over an environmental one that explains the incidence of the disease.

VL occurs in specific areas and can affect large numbers of people in many nations throughout the world, Eight-two percent are emerging nations. Within the past decade, major outbreaks have been reported in northeastern Brazil, India, Sudan, and in people with HIV-1 in southern Europe. Most VL cases in Latin America are caused by L chagasi. Elsewhere, most are caused by closely related species, L. donovani or L. infantum. A wasting disease is the result, marked by fever, massive enlargement of the liver and spleen, weight loss, and progressive suppression of the immune system. VL with symptoms is usually fatal if untreated. Yet 83% of Brazilians with a positive skin test to the antigen, or substance that triggers the immune response, do not have a history of disease symptoms-which means that they had had an asymptomatic infection, one without symptoms. The factors determining whether a person will have an asymptomatic infection or a progressive and possibly fatal one are not well defined. This study aims to explore the progression from infection to disease. A genome-wide scan, that is, a study of genetic material, will determine a person's tendency toward the infection or protection from it.

Participants of various ages living in the area where VL is common and who have a family member who was hospitalized with active VL may be eligible for this study. There will be an initial assessment of their health and exposure to VL, a process that usually takes about 3 days.

Patients will be asked about aspects such as the following:

  • Family structure.
  • Health, including history and date of VL, other diseases, symptoms, and medications.
  • Circumstances such as where they work or live, ownership of animals, and proximity to animal housing, and VL in dogs nearby.

Patients will be asked to answer a questionnaire and to undergo a physical exam, which includes vital signs, examination of lymph nodes, skin, lungs, cardiovascular system, abdomen, and extremities. They will be asked to donate a small amount of blood, approximately 10 to 20 ml, and to undergo skin tests that will determine whether they have been infected with the organisms that cause either VL or tuberculosis. If anyone if the family has signs of either of those diseases, he or she will be sent to a hospital for further study. Patients can also expect to have a cheek swab to obtain DNA and to have a tetanus vaccination. Blood and marrow samples will be used for the follow tests:

  • Immune responses to the parasite that causes VL.
  • Extraction of DNA and serum.
  • Blood cell counts.

Participants will be considered subjects of this study for 5 years.


Condition
Visceral Leishmaniasis

MedlinePlus related topics:   Leishmaniasis   

U.S. FDA Resources

Study Type:   Observational
Official Title:   Immunogenetics of Visceral Leishmaniasis

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   7000
Study Start Date:   October 2003

Detailed Description:

Visceral leishmaniasis is a potentially fatal disease caused in South America by the protozoan Leishmania chagasi. In neighborhoods with high exposure rates, the outcome of human infection with L. chagasi ranges from asymptomatic to a disseminated wasting disease called visceral leishmaniasis (VL). Several studies document familial clustering of VL in populations at risk. Segregation analyses favor a genetic over an environmental model for susceptibility to L. chagasi infection. A peri-urban outbreak of VL near the Universidade Federal do Rio Grande do Norte (UFRN) in Natal, northeast Brazil, has allowed us to identify endemic neighborhoods with ongoing transmission of L. chagasi infection. Natal is ideal for this study because endemic neighborhoods are easily accessible, people are motivated to cooperate with measures to control VL, and other forms of leishmaniasis are not transmitted in the region. Dr. Jeronimo of the UFRN, and Dr. Mary Wilson at University of Iowa have collected clinical data and DNA from 400 VL families living in these endemic neighborhoods. We have created an unprecedented cohort through which we can identify four distinct phenotypic responses after L. chagasi exposure. We documented familial clustering of L. chagasi infection, and results of both correlation and segregation analyses are consistent with the hypothesis that genetic factors predispose, in part, to the diverse clinical outcomes after infection. Polymorphism in the TNF locus is associated with developing symptomatic as opposed to asymptomatic disease after infection. We recently completed a genome-wide scan of the quantitative immune response (DTH) and identified potential linkage regions on chromosomes 2, 13, 15 and 19. We have also identified a small linkage peak on chromosome 9 for VL. In our ongoing study, we will next perform fine mapping of these regions using dense SNPs to identify genes that may determine susceptibility to L. chagasi infection. Additionally, we will also analyze candidate genes for association/linkage with susceptibility to or protection from L. chagasi disease. We recently identified an association on chromosome 5 with the DTH immune response among two linkage disequilibrium blocks spanning multiple immune related genes.

  Eligibility
Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria
  • INCLUSION CRITERIA:

We used three approaches to identify families in endemic neighborhoods, yielding three populations of families.

Population I: A neighborhood to the northeast of the city was identified through a family with two cases of disease.

Population 2: Individuals with suspected VL are admitted to one of three public hospitals in Natal. Families were interviewed and examined if they wished to participate.

Population 3: The neighboring families living closest to population 2 families were identified.

EXCLUSION CRITERIA

Individuals with ongoing illnesses other than VL were excluded from analyses.

Any medical conditions found or suspected based upon history, exam or blood tests were either treated by the investigators or referred to the appropriate medical facility in Natal.

Pregnant women and children less than 1 year were not given any skin test.

No exclusions based on ethnicity were done.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00342823

Contacts
Contact: Joan Bailey-Wilson, Ph.D.     (410) 550-7509     jebw@nhgri.nih.gov    

Locations
United States, Iowa
University of Iowa     Recruiting
      Iowa City, Iowa, United States, 52242
United States, Maryland
Johns Hopkins University     Recruiting
      Baltimore, Maryland, United States, 21205
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike     Recruiting
      Bethesda, Maryland, United States, 20892
Brazil
Universidade Federal do Rio Grande do Norte     Recruiting
      Natal, Brazil

Sponsors and Collaborators
  More Information

Publications:

Study ID Numbers:   999904024, 04-HG-N024
First Received:   June 19, 2006
Last Updated:   August 19, 2008
ClinicalTrials.gov Identifier:   NCT00342823
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Linkage Analysis  
Canidate Gene Analysis  
Genome Scan  
L. Chagasi  
Visceral Leishmania  

Study placed in the following topic categories:
Leishmaniasis
Protozoan Infections
Skin Diseases, Infectious
Skin Diseases
Parasitic Diseases
Leishmaniasis, Visceral

Additional relevant MeSH terms:
Skin Diseases, Parasitic
Sarcomastigophora Infections
Mastigophora Infections

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers